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Several medications such as baclofen, amitriptyline and even antiepileptic drugs such as carbamazepine or vigabatrin are known
to induce absence status epilepticus in patients with generalized epilepsies. Tiagabine (TGB) is effective in patients with focal
epilepsies. However, TGB has also been reported to induce non-convulsive status epilepticus in several patients with focal
epilepsies and in one patient with juvenile myoclonic epilepsy. In animal models of generalized epilepsy, TGB induces absence
status with 3–5 Hz spike-wave complexes.
We describe a 32-year-old patient with absence epilepsy and primary generalized tonic–clonic seizures since 11 years of
age, who developed her first absence status epilepticus while treated with 45 mg of TGB daily. Administration of lorazepam
and immediate reduction in TGB dosage was followed by complete clinical and electroencephalographic remission. This case
demonstrates that TGB can induce typical absence status epilepticus in a patient with primary generalized epilepsy.
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INTRODUCTION
Absence status epilepticus is defined as a generalized
absence seizure lasting for more than half an hour in
the context of a primary generalized epilepsy1. Dur-
ing the time of mental clouding of differing degree,
bilateral synchronous spike-wave discharges can be
recorded by EEG. Of all the forms of non-convulsive
status epilepticus, generalized absence status is the
most commonly encountered2. The incidence of ab-
sence status in patients with absence epilepsy is esti-
mated to be between 2 and 10%3.
Several antiepileptic drugs have been reported
to induce absence status in patients and animal
models. Tiagabine (TGB) inhibits the reuptake of
γ -aminobutyric acid (GABA) into the presynaptic
terminals and glia cells, thereby making more GABA
available at the synapses4. It increases the extracellular
concentration of GABA after oral administration5, 6. In
clinical trials TGB had a dose-related anticonvulsant
effect in patients with focal epilepsies7–11. However,
in animal models the frequency of interictal spike-
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wave discharges increased in rats when treated with
TGB12–14.
In addition, TGB was also reported to induce non-
convulsive status epilepticus in several patients with
partial epilepsy15, 16 and in one patient with juvenile
myoclonic epilepsy6. There have been no detailed re-
ports of this effect of TGB in patients with absence
epilepsy.
We describe a 32-year-old patient with absence
epilepsy and generalized tonic–clonic seizures since
the age of 11 years, in whom TGB induced her first
absence status.
CASE REPORT
A 32-year-old woman was admitted with absence sta-
tus epilepticus lasting for more than 6 hours.
At the age of 11 years, she began having absences
and generalized tonic–clonic seizures. The diagno-
sis of absence epilepsy was supported by generalized
spike-wave complexes during hyperventilation and a
positive family history for epilepsy. Seizures were
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Fig. 1: Thirty-two-year-old patient with absence status epilepticus lasting for more than 6 hours. This figure shows the EEG on
admission.
refractory to valproate, primidone, lamotrigine, and
clonazepam as monotherapy and in several combina-
tions. Initially, she had two to three absences per week
and one generalized tonic–clonic seizure every two
months. She has not experienced any absence seizures
and the frequency of generalized tonic–clonic seizures
declined to two per year since she was started on anti-
convulsants.
Lamotrigine was discontinued due to nausea and
TGB was added to sodium valproate by her neurolo-
gist. The dosage of valproate remained unchanged.
Routine EEGs were normal except for short bursts of
generalized spike-wave discharges under hyperventi-
lation.
In the first 6 months, up to a daily dosage of 30 mg,
the patient tolerated the new medication well and was
seizure-free except for one generalized tonic–clonic
seizure shortly after initiation of TGB therapy. There-
fore, the dose of TGB was increased to 45 mg/d at the
next follow-up visit. Within days, the patient repeat-
edly started to feel dizzy and experienced episodes of
‘lack of memory’. At this time, the EEG revealed in-
termittent generalized slowing and spike-wave com-
plexes during 30% of the recording.
On admission, the patient was treated with 2400 mg
valproate and 45 mg TGB. The serum level of val-
proate was 74 mg/l. She was admitted for an episode
lasting for more than 6 hours, during which she stared
and reacted slowly. She was unable to do simple cal-
culations (e.g. 3 × 3) but was fully oriented. She
responded slowly but adequately to other questions.
Within the previous 5 days before admission, she had
three similar episodes with mental clouding lasting
more than 4 hours each. She had never experienced
absences lasting for more than a minute before treat-
ment with TGB.
The EEG on admission revealed absence status
epilepticus (Fig. 1) with generalized spike-wave com-
plexes. Initially, she was given 600 mg of sodium-
valproate intravenously to booster the levels, however,
without any effect. After administration of 1 mg lo-
razepam, the EEG and the clinical picture rapidly nor-
malized.
Tiagabine was discontinued because a status epilep-
ticus inducing effect was suspected. The EEG re-
mained normal thereafter. The patient was discharged
on 2400 mg of sodium valproate. No further status
epilepticus occurred on follow-up 6 months later.
DISCUSSION
We report a patient with generalized epilepsy who de-
veloped EEG deterioration and her first absence sta-
tus epilepticus while taking TGB. Besides the tempo-
ral relation and the complete EEG normalization after
discontinuation of TGB, several additional lines of ev-
idence support that TGB induced the status epilepticus
in this patient and suggest a GABA-ergic mechanism.
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Observations in humans
TGB was reported to induce non-convulsive status
epilepticus in several patients with focal epilepsies and
in one patient with juvenile myoclonic epilepsy6, 15–17.
Other GABA-ergic medications such as baclofen or
vigabatrin18–22 have been reported to induce absence
status epilepticus in humans.
Animal data
In several animal models of absence epilepsy (i.e. a se-
lective strain of Wistar rats (WAG/Rij-rats) or genetic
absence epilepsy rats of Strasbourg (GAERS)), proab-
sence effects of vigabatrin and TGB have been demon-
strated6, 12, 23. After administration, TGB enhanced the
duration and the number of spike-wave discharges
in a dose-related fashion12. Furthermore, an unusual
second type of spike-wave discharges was recorded
during the treatment with TGB. These were consid-
ered to be forerunners of the genuine spike-wave dis-
charges13. At a higher TGB dosage, seven of 10 nor-
mal animals developed behavioural hyporeactivity and
simultaneously generalized 3–5 Hz spike-wave dis-
charges6.
GABA plays an important role in the pathophysi-
ology of absence seizures. The application of other
GABA-ergic drugs such as vigabatrin, an irreversible
inhibitor of the GABA-transaminase, or baclofen, a
GABA-agonist, to genetically absence-prone rats also
lead to an exacerbation of absence seizures and a
dose-related increase in spike-wave discharges22. The
synchronous spike-wave discharges during absence
seizures are generated by thalamo-cortical circuits be-
tween the reticular thalamic nucleus and thalamic re-
lay neurons as well as neocortical pyramidal cells.
This circuit is mediated by influences on the GABAB
and GABAA-receptors24, 25. An excessive stimulation
of these structures induces absence seizures24, 26.
In conclusion, TGB, a GABA-reuptake inhibitor,
can induce absences and absence status in patients
with absence epilepsy. This effect appears to be
mediated by a GABA-ergic mechanism. Therefore,
tiagabine should be used cautiously in the treatment
of generalized epilepsies. The EEG can be useful in
detecting an increased frequency of spike-wave com-
plexes after elevating the tiagabine dose.
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